Biocon Launches Affordable Bone Therapy Biosimilars

  Published 6 months ago

Biocon launches Bosanya and Aukelso biosimilars, expanding affordable osteoporosis and cancer bone therapies for patients.

  • Bosanya (60 mg/mL) treats postmenopausal osteoporosis, glucocorticoid‑induced loss; Aukelso (120 mg) prevents skeletal events in multiple myeloma
  • Both products received provisional interchangeability, allowing pharmacy‑level substitution under state regulations for greater patient access
  • Denosumab US sales hit $5 billion in 2024; Biocon aims to provide cheaper alternatives for patients

You might like these

Tata Units to Raise ₹2,000 Cr via Bonds

CarTrade Tech Q2 Profit Doubles

HAL: AMSEC Starts with 'Reduce' Rating

Imagicaaworld Secures ₹400 Crore Loan

Airtel Q1 Profit Jumps 57% YoY

Vintage Coffee Expands Capacity with New Investment

TCS & CEB: AI-Powered Reconciliation for Social Development

News that matters the most ⚡